From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications

Complications of pregnancy represent a significant disease burden, with both immediate and lasting consequences for mother and baby. Two key pregnancy complications, fetal growth restriction (FGR) and preeclampsia (PE), together affect around 10%–15% of all pregnancies worldwide. Despite this high i...

Full description

Bibliographic Details
Main Authors: Elizabeth C. Cottrell, Colin P. Sibley
Format: Article
Language:English
Published: MDPI AG 2015-06-01
Series:International Journal of Molecular Sciences
Subjects:
Online Access:http://www.mdpi.com/1422-0067/16/6/12907
id doaj-dbcaf1206445408584e08aee50c09bf9
record_format Article
spelling doaj-dbcaf1206445408584e08aee50c09bf92020-11-25T00:51:37ZengMDPI AGInternational Journal of Molecular Sciences1422-00672015-06-01166129071292410.3390/ijms160612907ijms160612907From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy ComplicationsElizabeth C. Cottrell0Colin P. Sibley1Maternal and Fetal Health Research Centre, Institute of Human Development, University of Manchester, Manchester M13 9WL, UKMaternal and Fetal Health Research Centre, Institute of Human Development, University of Manchester, Manchester M13 9WL, UKComplications of pregnancy represent a significant disease burden, with both immediate and lasting consequences for mother and baby. Two key pregnancy complications, fetal growth restriction (FGR) and preeclampsia (PE), together affect around 10%–15% of all pregnancies worldwide. Despite this high incidence, there are currently no therapies available to treat these pregnancy disorders. Early delivery remains the only intervention to reduce the risk of severe maternal complications and/or stillbirth of the baby; however early delivery itself is associated with increased risk of neonatal mortality and morbidity. As such, there is a pressing need to develop new and effective treatments that can prevent or treat FGR and PE. Animal models have been essential in identifying and screening potential new therapies in this field. In this review, we address recent progress that has been made in developing therapeutic strategies for pregnancy disorders, some of which are now entering clinical trials.http://www.mdpi.com/1422-0067/16/6/12907pregnancyfetal growth restrictionpreeclampsiapreclinical trials in pregnancy
collection DOAJ
language English
format Article
sources DOAJ
author Elizabeth C. Cottrell
Colin P. Sibley
spellingShingle Elizabeth C. Cottrell
Colin P. Sibley
From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications
International Journal of Molecular Sciences
pregnancy
fetal growth restriction
preeclampsia
preclinical trials in pregnancy
author_facet Elizabeth C. Cottrell
Colin P. Sibley
author_sort Elizabeth C. Cottrell
title From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications
title_short From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications
title_full From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications
title_fullStr From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications
title_full_unstemmed From Pre-Clinical Studies to Clinical Trials: Generation of Novel Therapies for Pregnancy Complications
title_sort from pre-clinical studies to clinical trials: generation of novel therapies for pregnancy complications
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1422-0067
publishDate 2015-06-01
description Complications of pregnancy represent a significant disease burden, with both immediate and lasting consequences for mother and baby. Two key pregnancy complications, fetal growth restriction (FGR) and preeclampsia (PE), together affect around 10%–15% of all pregnancies worldwide. Despite this high incidence, there are currently no therapies available to treat these pregnancy disorders. Early delivery remains the only intervention to reduce the risk of severe maternal complications and/or stillbirth of the baby; however early delivery itself is associated with increased risk of neonatal mortality and morbidity. As such, there is a pressing need to develop new and effective treatments that can prevent or treat FGR and PE. Animal models have been essential in identifying and screening potential new therapies in this field. In this review, we address recent progress that has been made in developing therapeutic strategies for pregnancy disorders, some of which are now entering clinical trials.
topic pregnancy
fetal growth restriction
preeclampsia
preclinical trials in pregnancy
url http://www.mdpi.com/1422-0067/16/6/12907
work_keys_str_mv AT elizabethccottrell frompreclinicalstudiestoclinicaltrialsgenerationofnoveltherapiesforpregnancycomplications
AT colinpsibley frompreclinicalstudiestoclinicaltrialsgenerationofnoveltherapiesforpregnancycomplications
_version_ 1725244805049483264